Author of

• 11818

  +

  P2.13 - Poster Session 2 - SCLC (ID 201)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 11824

    +

    P2.13-006 - A Phase IIa study of HA-Irinotecan, a CD44-targeted formulation of hyaluronic acid and irinotecan, in the treatment of extensive stage small cell lung cancer and its effect on cancer stem-like cells. (ID 2761)

    09:30 - 09:30  |  Author(s): P. Midolo
    • Abstract

    Background
    Preclinical studies in small cell lung cancer cell lines and xenograft models have shown that Hyaluronic acid (HA) can be effectively used to deliver Irinotecan (IR) and selectively decrease CD44 expressing (stem cell-like) tumour cells and prolong duration of response. This “proof of principle” study aims to replicate these findings in the clinical setting and obtain data on safety and response rates.

    Methods
    Extensive Small Cell Lung Cancer (ESCLC) patients with measurable disease (suitable for biopsy), PS 0-2, medically fit and able to give informed consent were screened for this study. A safety cohort (n=5) were treated with HA-IR (150mg/m[2]) and Carboplatin(C) at 5 AUC, q3 weekly with subsequent patients stratified as 1[st] or 2[nd] line. All 2[nd] line patients received open label HA-IR+C while 1[st] line patients were randomized to receive either HA-IR+C or equivalent dosing regimen of IR+C. Sequential tumour biopsies were obtained at baseline and after 1 or 2 cycles. Tumour response was measured by CT/PET scan at baseline, after 1 cycle and every 2 cycles subsequently. A final biopsy at disease progression was planned. Blood samples for circulating tumour cells (CTCs) were obtained at baseline, and at every cycle.

    Results
    Patients N=16, Age: median= 60; Range 39-78. Three 2nd line patients were not evaluated due to rapid early disease progression after Cycle 1. Overall toxicity profile of HA-IR+C was similar to IR+C with grade III/IV diarrhoea and neutropenia seen in 15% and 20% respectively. One patient (7%) had grade III anaemia, while no grade III/IV nausea or vomiting was observed. No biopsy related complications were observed. Of 13 patients evaluated for tumour response, the overall response rate was 60% with 1 (7%) complete and 7 (53%) partial responses. Three patients (24%) achieved stable disease while 2 patients (16%) progressed during the treatment. To date median progression-free survival is 5.9 months (7.6 months in first line and 3.1 months in the second line cohort). Preliminary CTCs data shows close correlation between the number of CTCs and tumour response and relapse. Patients with CD44+ tumours appear to have obtained most durable response. Analysis of sequential biopsies is underway and will be presented.

    Conclusion
    HA-IR+C appears to be an active option for ESCLC. This regimen is designed to target CD44[+ve] subpopulation within the tumour.